This Viewpoint discusses the spread of medetomidine in the US illicit opioid market and the need for monitoring and a public health response.
No takes yet. Share an insight, caveat, or question.
Palamar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: